pomalidomide has been researched along with B-Cell Chronic Lymphocytic Leukemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brander, DM; Ding, W; Gui, M; He, W; Huntington, SF; Iqbal, M; Kearney, AS; Koehler, AB; Leis, JF; Mato, AR; McKinlay, TP; Moustafa, MA; Rosenthal, AC; Schuster, SJ; Tun, HW | 1 |
| Wiernik, PH | 1 |
| Lentzsch, S; Pan, B | 1 |
| Chanan-Khan, A; Porter, CW | 1 |
| Czuczman, MS; Deeb, G; Hernandez-Ilizaliturri, FJ; Knight, J; Reddy, N; Roth, M; Vaughn, M; Wallace, P | 1 |
3 review(s) available for pomalidomide and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
Immunomodulating drugs for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Down-Regulation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Thalidomide | 2006 |
1 trial(s) available for pomalidomide and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
1 other study(ies) available for pomalidomide and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Drug Interactions; Immunohistochemistry; Immunosuppressive Agents; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, SCID; Microcirculation; Neovascularization, Pathologic; Rituximab; Thalidomide | 2008 |